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Statement of translational relevance 
The PI3K/AKT pathway is commonly activated in several tumor types. Selective targeting of 
p110β could result in successful pathway inhibition while avoiding the on and off target 
effects of pan-PI3K inhibitors. We present preclinical studies conducted to characterize the 
effect and define the optimal target population for development of GSK2636771, a selective 
p110β inhibitor, and results from a first-time-in-human clinical trial study indicating that 
GSK2636771 can be active in PTEN-deficient and/or PIK3CB-aberrant advanced solid 
tumors. Further Phase II clinical studies of GSK2636771 in combination with other agents, 
including androgen receptor antagonists, are currently underway based on these data. 
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Abstract  
Background: The phosphoinositide 3 kinase (PI3K)/protein kinase B (AKT) pathway is 
commonly activated in several tumor types. Selective targeting of p110β could result in 
successful pathway inhibition while avoiding the on and off target effects of pan-PI3K 
inhibitors. GSK2636771 is a potent, orally bioavailable, adenosine triphosphate-competitive, 
selective inhibitor of PI3Kβ. 
Methods: We evaluated the safety, pharmacokinetics, pharmacodynamics and antitumor 
activity of GSK2636771 to define the recommended Phase II dose (RP2D). During the dose-
selection and dose-escalation stages (Parts 1 and 2), patients with phosphatase and tensin 
homolog (PTEN)-deficient advanced solid tumors received escalating doses of GSK2636771 
(25–500 mg once daily [QD]) using a modified 3+3 design to determine the RP2D; tumor 
type-specific expansion cohorts (Part 3) were implemented to further assess tumor 
responses at the RP2D.  
Results: A total of 65 patients were enrolled; dose-limiting toxicities were 
hypophosphatemia and hypocalcemia. Adverse events included diarrhea (48%), nausea 
(40%), and vomiting (31%). Single- and repeat-dose exposure increased generally dose 
proportionally. GSK2636771 400 mg QD was the RP2D. Phospho/total AKT ratio decreased 
with GSK2636771 in tumor and surrogate tissue. A castrate-resistant prostate cancer 
(CRPC) patient harboring PIK3CB amplification had a partial response for over a year; an 
additional 10 patients derived durable (≥24 weeks) clinical benefit, including 2 other patients 
with CRPC with PIK3CB alterations (≥34 weeks). GSK2636771 400 mg QD oral induced 
sufficient exposure and target inhibition with a manageable safety profile.  
Conclusions: Genomic aberrations of PIK3CB may be associated with clinical benefit from 
GSK2636771.  
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Introduction  
Activation of phosphoinositide 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of 
rapamycin (mTOR) signaling (1), most commonly by activating mutations of PI3K/AKT family 
members or loss of phosphatase and tensin homolog (PTEN) phosphatase function, 
contributes to carcinogenesis of many malignancies (2-5). Inhibition of PI3K signaling has 
been challenging therapeutically, and inhibitors of PI3K have so far had limited clinical 
success (6,7). Reasons for this include biological feedback loops permitting the tumor to 
reactivate the pathway (8,9), activation of alternative pathways (10), and the non-specificity 
of pan-PI3K inhibitors, resulting in a plethora of PI3K-related and off-target toxicities that limit 
administration of clinically active doses for long enough (11). PI3K is composed of a 
heterodimer between a p110 catalytic subunit and a p85 regulatory subunit. The four 
described isoforms of the catalytic subunit are p110α, p110β, p110γ, and p110δ, encoded 
by genes PIK3CA, PIK3CB, PIK3CG, and PIK3CD, respectively (12). PI3K-isoform-selective 
inhibitors have been developed in attempts to reduce off-target toxicities seen with pan-PI3K 
inhibitors (13).  
Loss of PTEN deleted on chromosome ten function is common in a number of cancers, 
including glioblastoma, prostate, endometrial, melanoma, and breast cancers. Preclinical 
studies have indicated that the PI3Kβ isoform (containing the p110β catalytic subunit) is the 
critical lipid kinase that drives primarily PI3K pathway activation, cell growth and survival in 
PTEN-deficient tumor cells (14-17).  
We hypothesize that highly selective PI3Kβ inhibition would have utility in PTEN-deficient 
cancers, whilst avoiding toxicities associated with inhibition of other PI3K isoforms (18), in 
particular skin rash, hyperglycemia and diarrhea, or other off-target effects. This strategy 
would be expected to maximize therapeutic efficacy by enabling administration of 
appropriate doses and rational drug combinations with other agents, such as androgen 
receptor antagonists in PTEN-deficient prostate cancer (19-21), or erbB2 inhibitors and 
hormonal treatments in breast cancer (22-25).  
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GSK2636771 (Figure 1A), is a potent, orally bioavailable, adenosine triphosphate-
competitive, selective inhibitor of PI3Kβ with an apparent Ki value of 0.89 nM 
(IC50 = 5.2 nM), >900-fold selectivity over p110α and p110γ, and >10-fold selectivity over 
p110δ isoforms, while sparing other PI3K superfamily kinases (Figure 1B). While pan-PI3K 
inhibitors have been tested in clinical trials, to our knowledge, this is the first study of a truly 
selective inhibitor of PI3Kβ, which confers the advantage of avoiding on- and off-target 
toxicities associated with pan-PI3K inhibitors. 
Here we present preclinical data characterizing the selectivity of GSK2636771 in cell line 
and murine xenograft models, together with the results of a dose-finding, first-time-in-human 
study of GSK2636771 monotherapy in patients with PTEN-deficient or PIK3CB genomically-
altered advanced solid tumors. The aim of this first-time-in-human study was to further 
characterize the tolerability, safety and pharmacokinetic-pharmacodynamic (PK-PD) profile 
of GSK2636771, while also assessing its antitumor activity. We also pursued genomics 
analyses to identify any alterations as putative predictive biomarkers of antitumor response 
to determine the optimal target population.  
Materials and Methods  
Preclinical studies 
Cell lines and reagents 
Cell lines were obtained from ATCC (Manassas, Virginia, USA), cultured in the appropriate 
medium supplemented with 10% fetal bovine serum (Sigma−Aldrich, St. Louis, Missouri, 
USA) at 37C in humidified incubators under 5% carbon dioxide, and passaged no greater 
than 20 times. The cell lines were authenticated by short tandem repeat (STR) profiling and 
tested for Mycoplasma upon receipt using the ATCC Universal Mycoplasma Detection Kit. 
GSK2636771 was dissolved in dimethyl sulfoxide at a stock concentration of 20 mM. 
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Selectivity of GSK2636771 for PI3Kβ 
Biochemical selectivity of GSK2636771 was tested using the PI3-Kinase HTRF™ Assay 
(EMD Millipore, Billerica, Massachusetts, USA), as well as the entire panel of GSK in-house 
kinase selectivity assays. Affinity-enrichment based chemoproteomics using kinobeads was 
performed as described previously (26). Briefly, 14 lipid and atypical kinases were enriched 
from a standard mixture of extracts derived from HeLa, K562, and Jurkat cells using a 
compound-derivatized bead matrix. The enriched proteins were identified by quantitative 
mass spectrometry analysis, enabling the simultaneous assessment of binding specificity 
and potency for all detected affinity-captured proteins. 
Soft agar cell-viability assay 
Cells were cultured in 96-well plates (5 × 103 cells/well) and treated with GSK2636771 (dose 
range: 30.7 μM–1.6 nM) for 6 days in soft agar media (bottom layer: 0.6% final 
concentration; top layer: 0.3% final concentration). Cell proliferation was measured using the 
alamarBlue® Cell Viability Assay (Thermo Fisher, Waltham, Massachusetts, USA) according 
to the manufacturer’s instructions. One cell plate was developed with alamarBlue® reagent at 
the time of compound addition (T0 plate). Results were then expressed as a percentage of 
the T0 value (normalized to 100%) and plotted against the compound concentration after 6 
days of treatment. The cellular response was determined by fitting the concentration 
response data using a 4-parameter curve fit equation and determining the concentration that 
inhibited 50% of the Ymax-Ymin window (EC50). 
Western blot analysis 
HCC1954 and MDA-MB-468 breast cancer cells were treated with increasing concentrations 
of GSK2636771 for 24 hours. PC3 prostate cancer cells were treated with 1 or 10 µM 
GSK2636771 for up to 48 hours. Cells were lysed with 1X cell lysis buffer (Cell Signaling 
Technology, Danvers, Massachusetts, USA) containing protease and phosphatase inhibitors 
(Roche, Basel, Switzerland). Subsequently, 30–40 µg of protein was run on 4–12% Bis-Tris 
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gels (Thermo Fisher, Waltham, Massachusetts, USA), and protein was transferred onto 
nitrocellulose membranes (Thermo Fisher, Waltham, Massachusetts, USA). Membranes 
were blocked for 1 hour using Odyssey® Blocking Buffer (LI-COR Biosciences, Lincoln, 
Nebraska, USA), before immunoblotting using the following antibodies (all from Cell 
Signaling Technology, Danvers, Massachusetts, USA): pAKT Ser473 (#4060), pAKT Thr308 
(#13038), total AKT (#9272), pERK (#9101), total ERK (#4695), pS6 (#2211), total S6 
(#2317), PTEN (#9188), and p100β (#3011). Western blots were processed using Odyssey® 
CLx Imaging System (LI-COR Biosciences, Lincoln, Nebraska, USA). 
In vivo studies 
Female nude mice (Charles River Laboratories, Wilmington, Massachusetts, USA) were 
injected with 2.0 × 106 PC3 cells to establish subcutaneous PC3 tumor xenografts. Once 
tumors reached ~200–250 mm3, mice were randomized (n=8/group) and treated with vehicle 
or GSK2636771 at 1, 3, 10, or 30 mg/kg by oral gavage for 21 days. Tumor volume 
measurements and body weights were collected twice weekly. For PK/PD studies, mice 
bearing PC3 tumor xenografts (n=3/group) were dosed once orally with either vehicle or 
GSK2636771 at 3 and 10 mg/kg for 1, 2, 4, 6, 8, 10, and 24 hours. Blood was collected and 
mixed 1:1 with water, and tumors were excised into two halves with one half flash frozen in 
liquid nitrogen for compound concentration determination by the GSK Drug Metabolism and 
PK (DMPK) group. The other half of excised tumors was immediately processed using a 
sterile Medicon (BD Biosciences, San Jose, California, USA) in 1 mL Meso-Scale Discovery 
(MSD®) lysis buffer containing protease and phosphatase inhibitors. Phospho and total AKT 
protein levels were measured using the MSD Phospho (Ser473)/Total AKT Whole Cell 
Lysate enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer’s 
instructions. To measure glucose and insulin response, female nude mice (n=3/group) were 
dosed orally for 3 days with vehicle, 100 mg/kg GSK2636771, or 3 mg/kg GSK2126458 (a 
pan PI3K/mTOR inhibitor), then starved for 20 hours before receiving a final dose of 
compound followed by blood collection after 0, 0.5, 1, 2, and 4 hours. Compound 
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concentrations were determined by the GSK DMPK group, glucose was measured using an 
ACCU-CHEK® Compact Plus glucose meter (Roche, Basel, Switzerland), and insulin was 
measured from plasma using an ALPCO Mouse Insulin ELISA Kit. All animal studies were 
conducted in accordance with the GSK Policy on the Care, Welfare and Treatment of 
Laboratory Animals and were reviewed by the Institutional Animal Care and Use Committee 
at GSK. 
First-time-in-human study 
Study design 
The study followed a multi-stage design to maximize the number of patients receiving 
potentially active doses and prioritize acquisition of tumor tissue biopsies for PD analysis 
(Supplementary Figure 1). Part 1 was a dose selection stage, to assess the PK of 
GSK2636771 following single-dose administration and determine the optimal starting dose 
for Part 2. The primary objective of Part 1 was to establish a GSK2636771 dose that 
provided a median area under the concentration-time curve 0 to 24 hours (AUC[0–24]) at 
steady state of 10–50 µg*hr/mL. Part 2 was a dose-escalation stage utilizing a modified 3+3 
design and allowing enrollment of additional patients for PD analysis of tumor biopsies. The 
primary objectives of Part 2 were to determine a recommended Phase II dose (RP2D), 
further characterize the PK and PD of GSK2636771 after repeated daily dosing, and confirm 
the inhibition of PI3Kβ activity by GSK2636771 in tumor biopsies. Part 3 was an expansion 
cohort stage including patients with PTEN-deficient tumors and/or genomic PIK3CB genomic 
aberrations, to determine tumor responses to the RP2D of GSK2636771.  
Clinical trial oversight 
The study was designed by GSK representatives and study investigators. The research 
ethics committee at each participating site approved the study protocol. Data were collated 
and analyzed by GSK.  
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Trial population 
Patients with advanced solid tumors progressing on standard therapy were enrolled after 
providing written consent and based on eligibility criteria. These included: age ≥18 years; 
Eastern Cooperative Oncology Group performance status 0–1; adequate organ function 
including renal function (based on blood creatinine and urine protein/creatinine ratio); and 
normal left-ventricular ejection fraction (LVEF). Patients receiving medication impacting 
platelet aggregation or with a baseline platelet-function defect were excluded. Full eligibility 
criteria can be found in the Supplementary Appendix. 
For Parts 1 and 2, the target population were patients with PTEN-deficient tumors 
(determined by immunohistochemistry [IHC]) and one of the following primary tumor types: 
endometrial, ovarian, triple-negative breast cancer, castrate-resistant prostate cancer 
(CRPC), non-small cell lung cancer, glioblastoma, gastric adenocarcinoma, colorectal, head 
and neck squamous carcinoma, and melanoma. In Part 3, the expansion cohorts included 
patients with PTEN-deficient CRPC, colorectal cancer and/or genomic abnormalities (copy 
number gain or mutations) in PIK3CB. For eligibility purposes, PTEN assessments during 
the dose-escalation stage of the trial were performed at either the local laboratory of the 
investigator sites or at a central laboratory (Ventana Medical Systems, Tucson, Arizona, 
USA). In the expansion phase of the study, all samples were tested at the central laboratory 
(Ventana Medical Systems, Tucson, Arizona, USA) prior to enrollment and loss of PTEN 
function was defined as an H-score ≤30, with a maximum of 30% of cells at a 1+ staining 
intensity. A rabbit monoclonal anti-PTEN antibody (clone D4.3, catalog no. 9188, Cell 
Signaling Technologies, Danvers, Massachusetts, USA) was used for PTEN IHC staining. 
Treatment, starting dose, and dose-escalation 
Treatment was administered orally as white gelatin capsules containing 10, 25, or 100 mg of 
GSK2636771. Based on non-clinical toxicology studies predicting an AUC[0–24] in human 
subjects of 13 μg*hr/mL and a maximum observed plasma concentration (Cmax) of 
0.85 μg/mL at steady state, the starting dose in Part 1 was 25 mg. This was <1/20 of the 
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dose estimated with FDA recommendations for starting doses based on the highest non-
severely toxic dose (HNSTD) of 100 mg/kg/day, which was also the no observed adverse 
effect level (NOAEL) in canine studies. Part 2 followed a modified 3+3 design 
(Supplementary Table 1), starting at the selected dose from Part 1. Dose-limiting toxicities 
(DLTs) were defined as any Grade 3/4 non-hematological drug-related toxicity (apart from 
Grade 3 rash, diarrhea, nausea, vomiting or mucositis that responds to treatment within 48 
hours) occurring during the first 4 weeks of drug administration. Additionally, Grade 4 
neutropenia lasting >5 days, Grade 4 anemia, Grade 4 thrombocytopenia (or Grade 3 with 
bleeding), an 8-fold increase in transaminases (over the upper limit of normal), a >20% 
decrease in LVEF, or any toxicity leading to >25% of the planned dose being missed, were 
also considered DLTs. Dose escalation was pursued until the maximum tolerated dose was 
established, defined as the maximum dose level before DLTs were observed in ≥33% of 
patients.  
Study evaluations 
Adverse events (AEs) were recorded throughout the study, and graded based on Common 
Terminology Criteria for Adverse Events v4.0, including monitoring of changes in renal 
function via blood and urine tests and other vital signs assessments. Cardiac evaluations 
(echocardiograms/multigated acquisition scans) were performed at baseline and bi-monthly 
during treatment. Response to therapy was assessed every 8 weeks by computed 
tomography/magnetic resonance imagery (and whole-body bone scintigraphy for patients 
with CRPC) (27). Tumor markers were analyzed every 8 weeks if appropriate, according to 
tumor type. 
Blood samples for PK analysis were collected ≤1 hour pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 
24, 48, and 72 hours after single dose administration (Parts 1 and 2) and then ≤1 hour pre-
dose on Days 8 and 15 and ≤1 hour pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours after 
administration on Day 22 during the first cycle of continuous treatment (Part 2). Blood 
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samples at ≤1 hour pre-dose, 1–2 hours, 3–4 hours, 6–8 hours, and 22–26 hours post dose 
on Day 22 were collected in Part 3. 
Analyses of markers of target modulation (pSer473 AKT, pSer9 GSK3 and pThr421/Ser424 
P70S6K) were undertaken on platelet rich plasma (PRP) from patients during the dose-
escalation stage using MSDelectrochemiluminescent immunoassays validated to Good 
Clinical Practice standards. Changes in pSer473 AKT, pThr246 PRAS40, pSer235/236 
S6RP and pThr308 AKT were measured in tumor biopsies using IHC (H-scores) at 
pretreatment and Days 8–15 (2–4 hours post dose). 
Next-generation sequencing and copy number analyses 
Retrospective targeted next-generation sequencing of archival or fresh tumor samples was 
performed if tissue was available. DNA was extracted using the GeneRead™ formalin-fixed, 
paraffin-embedded DNA Isolation kit (Qiagen, Hilden, Germany; cat#180134) and libraries 
prepared utilizing a customized sequencing panel (Qiagen GeneRead v2; Supplementary 
Table 2) including PI3K/AKT pathway genes, and sequencing was carried out on an Illumina 
Sequencer. Copy number variation was determined using Nanostring or quantitative 
polymerase chain reaction platforms. Background corrected, normalized values relative to a 
normal (diploid) control for 1–3 probes were used for each gene.  
Functional characterization of the PIK3CB p.L1049R mutation in vitro 
BacMam vectors (pHTBV1.1) containing human wild-type (WT) p110β or mutant p110β 
(L1049R) were obtained from the GSK plasmid repository. Viral particles were generated 
and added into 6-well plates at a range of 0 to 500 multiplicity of infection. PC3 cells were 
then plated in the wells (1.0 × 106 cells/well) and allowed to incubate overnight. The media 
containing viral particles was removed and replaced with media lacking serum for 10 hours. 
PC3 cells were then lysed for Western blot analysis. 
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Statistical considerations 
The number of subjects in Parts 1 and 2 was dependent on the number of subjects enrolled 
to select a starting dose, characterize individual cohorts, and explore the PD profile. Planned 
enrollment for Part 3 included a minimum of 12 and maximum of 20 subjects in each Tumor-
Specific Expansion Cohort  
Descriptive statistics were used to summarise safety data in all patients who received at 
least one dose of GSK2636771. All patients who underwent sampling were included in the 
PK analyses, which used descriptive statistics to summarize AUC(0-t), AUC(0-24), Cmax, time to 
reach Cmax (Tmax), calculated using standard non-compartmental methods. Additionally, 
AUC(0-∞) and half-life were assessed after the single run-in dose. Tumor response rate was 
evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria 
(28). The data were analyzed with Statistical Analysis Software (SAS®, Cary, North Carolina, 
USA) v9.2. 
Results 
Preclinical studies 
To determine the effects of selectively inhibiting PI3Kβ activity on tumor cell growth and 
pathway signaling, a series of experiments was performed with GSK2636771 to compare its 
effects in PTEN-deficient and PTEN WT tumor cells. GSK2636771 primarily inhibited the 
growth of PTEN-deficient cancer cells in a cell line panel spanning multiple tumor types 
(Figure 1C). Inhibition of AKT and ribosomal S6 kinase phosphorylation was observed in a 
concentration- and time-dependent manner mainly in PTEN-deficient cells (Figures 1D and 
1E and Supplementary Figure 2). GSK2636771 had no effect on mitogen-activated protein 
kinase (MAPK) signaling, as evidenced by measurement of extracellular signal-regulated 
kinase (ERK) phosphorylation (Figure 1D). When administered orally in mice bearing PC-3 
prostate tumor xenografts, GSK2636771 resulted in tumor growth inhibition, and a dose- and 
time-dependent PK-PD response was observed (Figures 1F and 1G). Importantly, 
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GSK2636771 did not elevate glucose or insulin levels in mice compared with the pan 
PI3K/mTOR inhibitor, GSK2126458 (Supplementary Figure 3).  
First-time-in-human clinical study 
Patients and administered treatments 
Overall, 65 patients were enrolled and received at least one dose of study medication. Data 
from 3 patients in Part 1 (dose selection), 50 in Part 2 (dose-escalation and additional PD 
exploratory cohorts), and 10 as part of the expansion cohorts in Part 3 made up a cohort of 
63 patients. Data from the last 2 patients with known PIK3CB genomic alterations made up 
the overall trial population of 65, but were analyzed separately for some parameters and 
were not included in the PK-PD analyses. Baseline patient demographics and characteristics 
for the entire population are summarized in Table 1. Briefly, the median age of the study 
population was 62 years (range 30–79), 26 (40%) patients were female, and the most 
common tumor types were colorectal (n=23, 35%) and prostate cancers (n=12, 18%). All 
patients had received at least one previous anticancer treatment; 37 (57%) had received  
>4 anticancer treatments. In total, seven dose levels (25–500 mg QD) were investigated. 
Median time on treatment was 55 days (range 5–478). 
Selection of the starting dose for dose-escalation stage 
Three patients were enrolled in Part 1 of the study and received a single dose of 25 mg of 
GSK2636771. The geometric mean AUC[0–24] was 15.7 μg*hr/mL, which was within the 
prespecified target range of 10 to 50 μg*hr/mL. Consequently, 25 mg QD was selected as 
the initial dose for the dose-escalation stage.  
Safety, tolerability, and DLTs  
No DLTs were observed in any patient receiving 25–350 mg QD of GSK2636771. Dose-
escalation then continued to 500 mg QD, where 3 of 4 treated patients experienced a DLT 
(hypocalcemia [Grades 2 and 3] and hypophosphatemia [Grade 3]), during the first to third 
week of continuous treatment. One patient also experienced a Grade 1 creatinine elevation. 
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These toxicities, indicative of potential renal tubular damage, resolved after GSK2636771 
discontinuation (except for 1 with normalized phosphate levels but persisting Grade 1 
hypocalcemia); 2 of the 3 patients were able to continue GSK2636771 treatment at a lower 
dose. An intermediate lower dose of 400 mg QD was explored (n=6), and no DLTs were 
observed. As such, 400 mg QD was selected as the RP2D.  
All 65 patients experienced at least one AE during the study; 60 patients experienced AEs 
that were considered to be related to the study drug (Table 2). The most common AEs 
across all dose levels (any; treatment-related) were gastrointestinal (diarrhea [n=31, 48%; 
n=27, 42%], nausea [n=27, 41%; n=18, 28%], vomiting [n=20, 31%; n=12, 18%]), and 
fatigue (n=17 [26%], n=14, 22%) (Table 2). AEs by dose-level are shown in Supplementary 
Table 3. Overall, 10 (15%) patients had treatment permanently discontinued due to an AE. 
Reasons for discontinuation were fatigue (n=1 in the 25 mg dose escalation cohort); 
fatigue/nausea (n=1) and hypophosphatemia/hypocalcemia (n=1), both in the 500 mg dose 
escalation cohort; proteinuria (n=1; 200 mg); pain (n=1), increased N-terminal prohormone 
brain natriuretic peptide/upper respiratory tract infection (n=1) and small intestinal 
obstruction (n=1), all with 350 mg of GSK2636771; and dyspnea (n=1), fatigue/vomiting 
(n=1), and urinary retention (n=1), all in the 400 mg expansion cohort. Dose reductions were 
required during trial treatment by 4 of 18 (22%) patients treated at the RP2D of 400 mg QD. 
Forty-one serious AEs (SAEs) occurred in 24 (37%) patients. Nine SAEs in 5 patients were 
considered related to the study drug (nausea, fatigue, hypocalcemia, and 
hypophosphatemia in 1 patient, increased creatinine and decreased appetite in 1 patient, 
and vomiting, urinary retention and pruritic rash in 1 patient each). Apart from the Grade 1 
increased creatinine, related SAEs were Grade 2 or 3. One patient experienced dyspnea 
which had a fatal outcome, but the event was considered not related to study treatment. The 
primary cause of death for this patient was disease under study. Eight (12%) additional 
deaths occurred during the study, all of which were considered related to the underlying 
disease.  
Research. 
on August 14, 2017. © 2017 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 23, 2017; DOI: 10.1158/1078-0432.CCR-17-0725 
 17 
Hyperglycemia, which has been reported when targeting other nodes in the 
PI3K/AKT/mTOR pathway, (29) was reported in 36 (55%) patients receiving GSK2636771 
treatment and was predominantly mild in severity; only 2 (3%) incidences of hyperglycemia 
were reported as AEs (Grade 1 in 1 patient and Grade 2 in the other). No cases of drug-
related grade ≥3 hyperglycemia were observed in this study. Cutaneous toxicity was 
uncommon: 10 cases (15%) of skin rash were documented across all dose levels (4 of which 
were in the GSK2636771 400 mg QD group). In addition, 3 cases of pruritic rash (200 mg 
and 500 mg QD dose escalation cohorts and 400 mg QD expansion cohort) and 3 cases of 
maculopapular rash (50 mg QD PD, 350 mg QD dose escalation, and 400 mg QD expansion 
cohorts) were reported. Other than the aforementioned cases of hypophosphatemia and 
hypocalcemia, evidence for renal tubular toxicity also included proteinuria, which was 
reported in 4 (6%) patients: 1 in each of the GSK2636771 50 mg, 200 mg, 350 mg, and 500 
mg QD dose groups. 
PK-PD 
PK-PD data are reported for the N=63 cohort. Following a single run-in dose of 
GSK2636771, drug exposure (Cmax, AUC) increased dose proportionally up to 350 mg, with 
below-proportional increments above this dose. The median Tmax was 4 hours (range 1–10 
hours). Blood concentrations declined in a monophasic manner with a geometric mean half-
life between 13 and 23 hours. Single-dose PK data are shown in Supplementary Tables 4 
and 5. Similar dose-proportional findings (for both AUC(0–τ) and Cmax) were observed after 
repeated daily oral dosing at Day 22, with ratio of AUC(0-∞) versus AUC(0–τ) suggesting 
steady-state had been achieved (Table 3 and Supplementary Table 6). PK parameters for 
the PD cohorts and concentrations in patients (n=2) in Part 3 were similar to those observed 
in the dose-escalation cohorts. 
GSK2636771 doses above 200 mg consistently resulted in blood concentrations greater 
than 0.6 μg/mL, the level predicted to robustly inhibit PI3Kβ from preclinical experiments. At 
the RP2D of 400 mg QD, pre-dose concentrations remained above 3.04 μg/mL from Week 2 
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onward, Tmax ranged between 1.02 and 5.8 hours post dose, and AUC(0–τ) had a geometric 
mean of 205 μg/mL. 
Inhibition of PI3K signaling was observed in PRP with GSK2636771 doses of 100–500 mg 
QD; the median percentage decrease from baseline at all post-dose time points was ≥61% 
for pSer473/Total AKT (Figure 2A) and ≥60% for pSer9/Total GSK3β (Figure 2B). At Day 1, 
the inhibitory effects were shown to be greatest 1–2 hours post dose with inhibition duration 
increasing from 10 hours to 24 hours at GSK2636771 doses ≥100 mg (data not shown).  
In 4/5 (80%) patients who received the RP2D of 400 mg QD decreases in pSer473 AKT and 
its downstream target (pThr246 PRAS40) were observed in paired tumor biopsies (pre- and 
on-treatment) (Figures 2C and 2D). Decreases in pSer235/236 S6RP and pThr308 AKT 
were also observed in 2/4 (50%) and 2/5 (40%) of evaluable patients, respectively (Figures 
2C and 2D).  
Antitumor activity 
Of the total 65 enrolled patients, we observed 1 partial response (PR), 21 stable disease 
(SD); 3 non-complete response (CR)/non-progressive disease (PD); 35 PD and 5 non-
evaluable investigator-assessed best responses (based on RECIST 1.1 criteria). No CRs 
were reported. One patient with metastatic CRPC treated with GSK2636771 200 mg QD 
during the dose-escalation phase experienced a confirmed PR, as well as a 78% fall in his 
prostate-specific antigen levels. The response was durable with progression after 68 weeks 
of treatment (Figure 3A–C). An additional 10 patients treated with GSK2636771 remained on 
therapy and free of progression for at least 24 weeks, including 2 more patients with CRPC 
(34 and 57 weeks), 5 colorectal (25–33 weeks), 1 endometrial (33 weeks), 1 gastric (25 
weeks) and 1 non-small cell lung cancer (33 weeks). 
Association between antitumor activity and genomic biomarkers 
Archival or fresh tumor biopsy samples from 55 patients participating in the study were 
retrieved. Of those, 48 (87%) passed quality control for next-generation sequencing. Overall, 
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5 patients had PIK3CB copy number gains or a putatively activating mutation (Figure 3D and 
Supplementary Tables 7–9); upon including the 2 additional patients with known PIK3CB 
aberrations at enrollment, 3/7 (43%) patients with PIK3CB genomic aberrations were on trial 
for ≥6 months. All 3 of these patients had CRPC, and remained on GSK2636771 treatment 
for 34, 57, and 68 weeks, respectively (the latter being the single patient with a PIK3CB copy 
number gain, exhibiting an investigator-assessed radiological PR). A cervical cancer patient 
harboring a known PIK3CB copy number gain received 22 weeks of GSK2636771 
treatment, and showed a differential radiological response in lymph nodes (best overall 
response: SD). 
Lastly, we analyzed the frequency of genomic events in other tumor suppressor and cancer 
promoting genes in the trial population. PIK3CA activating mutations were identified in 11 
patients, with 1 additional patient showing a PIK3CA copy gain; 9 of these tumors harbored 
mutations in the RAS/RAF pathway, 3 in ataxia telangiectasia mutated (ATM), a key element 
of DNA damage response, and one in BRAF (Figure 3D). Interestingly, all but one of these 
were mutually exclusive with PIK3CB aberrations in this population and did not correlate with 
antitumor responses. 
The p.L1049R mutation identified in a patient with CRPC, who achieved prolonged SD, is 
homologous to the very well-characterized PIK3CA hotspot mutation p.H1047R reported in 
cancer (Supplementary Figure 4A and 4B). In order to assess the functional relevance of the 
p.L1049R PIK3CB mutation, we transduced PC3 cells with pHTBBV1.1 (using baculovirus 
gene transfer into mammalian cells) expressing WT or the p.L1049R mutant at a range of 
multiplicity of infections. After 12 hours, substantially higher levels of pSer473 AKT were 
observed in cells with the p.L1049R mutation compared with WT cells (Supplementary 
Figure 4C), suggesting an activating and potentially driving function for this mutation. Similar 
findings have now been reported for other mutations in the same region of PIK3CB (30,31). 
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Discussion  
We here report on a first-time-in-human trial of GSK2636771, an oral selective PI3Kβ 
inhibitor. DLTs were identified and guided the selection of the RP2D, which was also 
supported by PK/PD data. Renal tubular damage, presenting in the form of 
hypophosphatemia, hypocalcemia, and proteinuria, was dose dependent, reversible, and 
manageable. Hyperglycemia and rash, typically reported for pan PI3K inhibitors, were 
uncommon. Also, GSK2636771 did not elevate insulin levels in mice compared with a pan 
PI3K/mTOR inhibitor. Furthermore, no hemorrhagic events or coagulation alterations were 
observed, despite preclinical data indicating that PI3Kβ plays an important role in adenosine 
diphosphate-induced platelet aggregation (32). 
Target inhibition was demonstrated at tolerated doses. Repeat-dose exposure appeared to 
increase in a generally dose-proportional manner. GSK2636771 doses >200 mg QD 
consistently resulted in blood concentrations >0.6 μg/mL, the level predicted to robustly 
inhibit PI3Kβ from preclinical experiments. The observed inhibitory effect of GSK2636771 on 
pAKT (Ser473) and other biochemical markers (eg, pGSK3β [Ser9]) in PRP confirmed an 
effective modulation of the PI3K pathway across doses. The RP2D of 400 mg QD was 
selected based on safety data. Significant target inhibition observed in tumor biopsies at this 
dose supported its selection.  
Several genomic landscape studies of different tumor types have identified that the 
PI3K/AKT pathway is altered in squamous cell lung (33), endometrial and head and neck 
cancers (34) and advanced prostate (35) and ovarian (36) cancers. However, in tumor types 
where activation of PIK3CA is more common, such as breast or colorectal cancer, genomic 
aberrations in PIK3CB are rare (<2%) (3,37). We, therefore, pursued retrospective tumor-
targeted next-generation sequencing to explore putative predictive biomarkers of antitumor 
activity.  
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Activating mutations in PIK3CA have been previously associated to responses to pathway 
inhibitors (38); mutations leading to activation of PIK3CB have been reported in different 
tumour types but their clinical relevance remains to date unknown (31,39). Of 48 samples 
analyzed in the current study, interestingly, 5 (10%) had PIK3CB aberrations, namely 4 
patients with copy number gains and 1 with an activating mutation (p.L1049R). Additionally, 
2 patients harboring PIK3CB copy number gains that were previously determined were also 
enrolled in the expansion phase. Among these 7 patients, we observed one durable 
radiological PR (on treatment for 68 weeks) and prolonged SD (on treatment for 34 and 57 
weeks) in the CRPC subset. This association, albeit preliminary, is of particular interest in 
advanced prostate cancer, where molecular stratification for therapy selection remains an 
unmet medical need. However, the patient population investigated here was very small and 
further studies are needed to fully determine the role of PIK3CB aberrations and indeed 
other biomarkers in the molecular stratification of patients when targeting this pathway. 
Importantly, several patients without PIK3CB aberrations benefited from therapy with 
prolonged SD. Therefore, PIK3CB aberrations do not fully explain the responses observed, 
highlighting the complexity of the PI3K/AKT/mTOR signaling pathway and the likely need for 
combination therapy to drive robust anti-tumor responses. The study was limited by the pre-
selection of patients with PTEN-deficient tumors, which did not allow for assessment of the 
impact of genetic aberrations in non-PTEN deficient tumors. Moreover, mostly archival 
rather than fresh tumor biopsies were analyzed which precluded the detection of aberrations 
that may emerge during tumor evolution (35,40). Despite this, the preliminary results 
presented here are of interest and form the basis for further studies into the association of 
PIK3CB aberrations with clinical benefit. Further studies will also be needed to better 
characterize the mechanisms associated with tubular damage at high doses, although these 
were not a concern at the RP2D. 
In conclusion, 400 mg QD continuous dosing was established as the RP2D for GSK2636771 
based on DLTs. The safety profile of GSK2636771 400 mg QD, together with proof-of-target 
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modulation and the preliminary association of clinical benefit with PIK3CB genomic 
aberrations, support the continued evaluation of this compound in Phase II clinical trials. The 
antitumor activity of GSK2636771 is being further studied as a single agent in molecularly-
defined populations within the NCI-MATCH clinical trial, in combination with the androgen 
receptor antagonist enzalutamide (Xtandi®) in CRPC, in combination with paclitaxel in gastric 
cancer, and in combination with immunotherapy in melanoma.  
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Tables  
Table 1. Baseline patient demographics and clinical characteristics 
 Total (N=65) 
Age, years  
   Mean (SD) 
   Median (range) 
 
59.7 (11.13) 
62.0 (30–79) 
Female, n (%) 26 (40) 
Race, n (%) 
   African American/African 
   Asian (Central/Southern) 
   Asian (Eastern) 
   Caucasian 
   Unknown 
 
2 (3) 
1 (2) 
13 (20) 
48 (74) 
1 (2) 
Primary tumor type, n (%)  
   Colon/rectum 23 (35) 
   Prostate 12 (18) 
   Gastric/GE junction 7 (11) 
   Breast (triple negative) 6 (9) 
   Ovary/fallopian tube 5 (8) 
   Endometrium/uterus 3 (5) 
   NSCLC 3 (5) 
   CNS 2 (3) 
   Head and neck 2 (3) 
   Melanoma 1 (2) 
   Cervix 1 (2) 
ECOG status, n (%) 
   0 
   1 
 
37 (57) 
28 (43) 
Prior lines of therapy, n (%) 
   1 
   2 
   3 
   4  
   >4 
 
7 (11) 
9 (14) 
4 (6) 
8 (12) 
37 (57) 
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CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group;  
GE, gastroesophageal junction; NSCLC, non-small cell lung cancer; SD, standard 
deviation. 
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Table 2. Summary of AEs and treatment-related AEs occurring in ≥10% 
of all patients, by grade 
 
Preferred term, n (%) Any AE Treatment-related AE 
 Total (N=65) Total (N=65) 
 Any grade Grade ≥3 Any grade Grade ≥3 
Any AE  65 (100) 33 (51) 60 (92) 15 (23) 
   Hypophosphatemia 8 (12) 6 (9) 6 (9) 5 (7) 
   Rash 10 (15) 3 (5) 5 (8) 3 (5) 
   Fatigue 17 (26) 3 (5) 14 (22) 2 (3) 
   Hypocalcemia 9 (14) 2 (3) 6 (9) 2 (3) 
   Diarrhea 31 (48) 1 (2) 27 (42) 1 (2) 
   Nausea 27 (41) 2 (3) 18 (28) 1 (2) 
   Vomiting 20 (31) 2 (3) 12 (18) 1 (2) 
   Decreased appetite 15 (23) 1 (2) 9 (14) 1 (2) 
Increased aspartate 
aminotransferase   
8 (12) 2 (3) 5 (8) 1 (2) 
   Hypertension 6 (9) 2 (3) 3 (5) 1 (2) 
   Rash maculopapular 3 (5) 1 (2) 3 (5) 1 (2) 
   Rash pruritic 3 (5) 1 (2) 3 (5) 1 (2) 
   Hypoalbuminemia 4 (6) 2 (3) 2 (3) 1 (2) 
   Increased NT-proBNP  3 (5) 1 (2) 2 (3) 1 (2) 
   Proteinuria 4 (6) 1 (2) 2 (3) 1 (2) 
   Dehydration 3 (5) 3 (5) 1 (2) 1 (2) 
   Nephropathy 1 (2) 1 (2) 1 (2) 1 (2) 
   Urinary retention 2 (3) 1 (2) 1 (2) 1 (2) 
   Dysgeusia 4 (6) 0 (0) 4 (6) 0 (0) 
   Headache 13 (20) 1 (2) 4 (6) 0 (0) 
   Increased blood creatinine 9 (14) 0 (0) 4 (6) 0 (0) 
AE, adverse event; NT-proBNP, N-terminal prohormone brain natriuretic peptide. 
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Table 3. PK parameters following repeated daily oral dosing of GSK2636771 (PK population) 
PK parameter, n (%) Dose 
selection 
cohort 
Dose escalation cohort 
 25 mg 
n=3 
25 mg 
n=6 
50 mg 
n=4 
100 mg 
n=3 
200 mg 
n=3 
350 mg 
n=7 
400 mg 
n=6 
500 mg 
n=4 
Cmax, ng/mL* n=2 
1459 (13) 
n=5 
1770 (65) 
n=4 
2336 (43) 
n=3 
2882 (85) 
n=3 
13175 (6) 
n=4 
16452 (9) 
n=6 
15078 (55) 
n=2 
29530 (71) 
Tmax, h, median 
(range) 
n=2 
8.96  
(8.03, 9.88) 
n=5 
4.05 
(3.00, 6.07) 
n=4 
4.05 
(4.03, 6.00) 
n=3 
3.25 
(3.10, 8.02) 
n=3 
23.9 
(3.22, 23.92) 
n=4 
3.60 
(2.03, 8.85) 
n=6 
2.01 
(1.02, 5.80) 
n=2 
6.33 
(2.58, 10.08) 
AUC(0–τ), h·ng/mL* n=2 
26181 (23) 
n=4 
28951 (77) 
n=4 
33052 (31) 
n=2 
30866 (136) 
n=1 
189479 (-) 
n=4 
282665 (25) 
n=5 
205014 (41) 
n=2 
485325 (70) 
*Data presented as geometric mean (CVb%). 
AUC(0–τ), area under the time concentration-time curve over the dosing interval; Cmax, maximum observed plasma concentration; CVb, 
coefficient of biological variation; PK, pharmacokinetic; Tmax, time to reach Cmax.
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Figure legends 
Figure 1. GSK2636771 is a potent, selective inhibitor of PI3Kβ that exhibits 
antitumor activity in PTEN-deficient cancers. 
A, chemical structure of GSK2636771. B, The selectivity of GSK2636771 for PI3Kβ 
against other PI3K isoforms and PI3K family members was tested in a biochemical 
activity assay (left column) and using a cancer cell lysate-based chemoproteomics 
approach to measure binding affinity (right column). C, Anchorage independent 
tumor cell growth was measured after 6 days of GSK2636771 treatment (dose range: 
0.16–3.07 µM) comparing PTEN WT with PTEN-deficient cells. Error bars 
correspond to SD. D, HCC1954 and MDA-MB-468 breast cancer cells were treated 
with increasing concentrations of GSK2636771 for 24 hours, and lysates were 
probed by Western blot using the indicated antibodies. E, PC3 prostate cancer cells 
were treated with GSK2636771 1 or 10 µM for up to 48 hours and probed with the 
indicated antibodies. F, Mice bearing subcutaneous PC3 tumor xenografts 
(n=8/group) were treated with vehicle or GSK2636771 (1, 3 or 10 mg/kg) once daily 
by oral gavage for 21 days, and tumor volumes were assessed. Error bars 
correspond to standard error of the mean. G, PK/PD relationship of GSK2636771 
was tested in mice bearing PC3 tumor xenografts (n=3/group) dosed once orally with 
either vehicle, 3 mg/kg or 10 mg/kg of GSK2636771. Tumors and blood samples 
were harvested at the indicated time points to measure plasma compound 
concentration and the ratio of pAKT to total AKT in tumors using enzyme-linked 
immunosorbent assays. The numbers above the bars indicate percent inhibition of 
pAKT relative to vehicle-treated tumors. Error bars correspond to SD. 
 
AKT, protein kinase B; mTOR, mammalian target of rapamycin;  
PD, pharmacodynamics; PI3K, phosphoinositide 3 kinase; PK, pharmacokinetic; 
PTEN, phosphatase and tensin homolog, SD standard deviation. 
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Figure 2. GSK2636771 inhibits PI3K signaling at doses of 100–500 mg QD 
Median values of pAKT/total AKT ratio A, and pGSK3β/total GSK3β. B, were 
measured in platelet rich plasma on Day 1, Cycle 1, using Meso Scale Discovery 
electrochemiluminescent assay (n=3 replicates per sample). C, changes in pSer473, 
pThr246 PRAS40, pSer235/236 and pThr308 were measured in tumor biopsies 
using IHC (H-scores) at pre-treatment and Days 8–15 (2–4h post dose) (n=1). D, 
representative photomicrographs (20x magnification) of IHC staining showing tumor 
PD effects of p-AKT (Ser473, Thr308), p-PRAS40 (Thr246) and pSer6RP 
(Ser235/236) for 2 patients treated with GSK2636771 400 mg QD (melanoma and 
TNBC). Biopsies were collected 2–4 hours post dose between Day 8 and 15. *p<0.05 
Paired t-test. 
 
AKT, protein kinase B; PD, pharmacodynamics; QD, once daily; TNBC, triple 
negative brain cancer. 
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Figure 3. Summary of antitumor activity of GSK2636771 in the first-in-man trial, 
and association with putative predictive biomarkers. 
A, Treatment duration in the 65 patients showed that 1 patient with CRPC had a PR, 
24 patients had SD or non-CR/non-PD, 7 of whom received GSK2636771 treatment 
for ≥6 months. B, The PR was observed at Week 24 in the patient with CRPC, and 
was accompanied by a 78% reduction in PSA levels. C, which was durable with 
progression after 68 weeks of treatment (n=1). D, Summary of data for 55 patients 
whose tumor tissue was analyzed retrospectively for somatic mutations and copy 
number alterations: one copy loss (light green); two copy loss (dark green); gain 
(light red); amplification (dark red); coding mutations (M); non-coding mutations (M*); 
no data (gray). CNV was determined based on Nanostring or qPCR platforms. 
 
CNS, central nervous system; CNV, copy number variation; CRPC, castrate-resistant 
prostate cancer; GE, gastroesophageal junction; PD, pharmacodynamics; PR, partial 
response; PSA, prostate-specific antigen; qPCR, quantitative polymerase chain 
reaction. 
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